ArticleMikrochimica acta2026
Superior oxidase-mimetic gadolinium vanadate nanoparticles for sensitive enzyme-free colorimetric detection of uric acid.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A novel, enzyme-free, colorimetric sensing platform for the sensitive and selective detection of uric acid (UA), based on the oxidase-mimetic activity of gadolinium vanadate (GdVO₄) nanoparticles is presented. The GdVO₄ nanozyme effectively catalyzed the oxidation of 3,3',5,5'-tetramethylbenzidine (TMB) into a blue-colored product, which was subsequently reduced by UA, resulting in a measurable decrease in absorbance at 655 nm. This assay provided a wide linear range (0.01-500 µM), a low detection limit (0.0023 µM), and a rapid response time (5 min). Mechanistic studies confirmed that reactive oxygen species (•OH, O₂•⁻, and ¹O₂) mediate the catalytic process. The platform showed favorable stability, reproducibility, and selectivity toward UA, even in the presence of common interferents. Moreover, the method was successfully applied to human serum samples, with recoveries ranging from 95.0% to 105.0%. A smartphone-assisted paper-based device enabled portable UA detection over a linear range of 5-460 µM with a detection limit of 1.38 µM. Collectively, these results establish GdVO₄ as effective nanozyme for simple, cost-effective, and portable colorimetric sensing of UA in clinical and point-of-care settings.
Indexed as
Identifiers
42274794What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.